Using a novel aptamer（适体，适配子） -based proteomics（蛋白质组） array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic（胰腺的） and mesothelioma（间皮瘤） . This technology would enable better clinical diagnosis¹ at an earlier stage and may provide insight into new therapeutic² targets, said Rachel Ostroff, Ph.D., clinical research director of Somalogic Inc.

"Currently these cancers are detected at an advanced stage, where the possibility of cure is minimal," said Ostroff. "Detection of these aggressive cancers at an earlier stage would identify patients for early treatment, which may improve their survival and quality of life."

Ostroff presented results of this ongoing³ study at the Fourth AACR International Conference on Molecular⁴ Diagnostics in Cancer Therapeutic Development.

Discovered about 20 years ago, aptamers are nucleic acid（核酸） molecules⁵ that bind⁶ to specific proteins. SomaLogic has developed the next generation of aptamers, SOMAmers (Slow Off-rate Modified Aptamers), which have superior affinity⁷（密切关系，吸引力） and specificity. SOMAmers enable a highly multiplexed proteomic（蛋白质生物学的） platform used for simultaneous identification and quantification of target proteins in complex biological samples.

The goal of this study was to determine if this proteomics technology could identify blood-based biomarkers for pancreatic cancer or mesothelioma in people diagnosed, but not yet treated, for cancer.

Participants in the control group had symptoms that resembled these cancers, but were benign⁸（良性的） (i.e. pancreatitis or lung fibrosis).

Ostroff and colleagues tested blood from participants to discover the biomarkers specific to those with cancer, which would then be used to identify these diseases at an early stage, where the potential for effective treatment is much higher than in disease that has progressed.

For both forms of cancer, the researchers discovered biomarkers and developed a signature with high accuracy for detection of each form of cancer. Equally important, they found high specificity, meaning few people without disease will be incorrectly diagnosed and thus avoid unnecessary tests or treatments.

"Validation⁹ studies are underway, which we hope will lead to the development of diagnostic tests that hold clinical benefits for patients," Ostroff said.

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. Mesothelioma is an asbestos（石棉） -related pulmonary（肺的） cancer that causes an estimated 15,000 to 20,000 deaths per year worldwide.